Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript
Pacira BioSciences, Inc. misses on earnings expectations. Reported EPS is $0.62 EPS, expectations were $0.64.
Pacira Biosciences Inc. (PCRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 37,050,000 | $35,149,520 | +24% | 1.84% | |
| 2. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,055,500 | $30,841,710 | 0.78% | |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 811,352 | $23,707,705 | +69% | 0.03% |
| 4. | 22,500,000 | $21,369,445 | 0% | ||
| 5. | Doma Perpetual Capital Management Pedro Escudero | 725,635 | $21,203,054 | +290% | 12.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.50 | 2,500 | Officer | 25,237 | 2020-03-11 | Filing | |
| $39.14 | 1,000 | Director | 10,277 | 2019-03-06 | Filing | |
| $38.72 | 700 | Director | 9,277 | 2019-03-06 | Filing | |
| $46.18 | 4,500 | Director | 32,819 | 2018-11-19 | Filing | |
| $51.29 | 4,000 | Director | 28,319 | 2018-11-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.25 | 2,836 | Officer | 95,557 | 2024-07-02 | Filing | |
| $28.72 | 3,970 | Officer | 38,075 | 2024-06-12 | Filing | |
| $28.57 | 5,012 | Officer | 44,569 | 2024-06-11 | Filing | |
| $28.38 | 1,000 | Officer | 116,040 | 2024-06-13 | Filing | |
| $28.38 | 880 | Director | 12,724 | 2024-06-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,114,251 | $273,774,827 | 0% | |
| 2. | 5,098,424 | $172,020,826 | 0% | |
| 3. | 2,084,542 | $70,332,448 | 0.71% | |
| 4. | 1,936,158 | $65,325,971 | 0% | |
| 5. | 1,411,767 | $47,632,711 | 0.01% |
News See All
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts.
5 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the five best small cap pharma stocks to invest in.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript
Pacira BioSciences, Inc. reports earnings inline with expectations. Reported EPS is $0.89 EPS, expectations were $0.89. Pacira BioSciences, Inc.
Hedge Funds are Betting on These 14 Sliding Stocks
Stocks jumped on December 6 after the release of yet another welcome data point for the Federal Reserve, showing the central bank’s consistent rate hikes in 2023 might finally be working.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q3 2023 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only mode.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Q2, 2023 Pacira BioSciences Inc. Earnings Conference Call. At this time, all participants are in listen-only mode.
5 Best Small Cap Pharma Stocks to Buy
In this piece, we will take a look at the five best small cap pharma stocks to buy.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q1 2023 Pacira BioSciences Inc Earnings Conference Call. All participants are in a listen-only mode.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Quarter Four 2022 Pacira BioSciences, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
